BVS — Bioventus Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1665988 ·
Last close
$14.02
Market Cap
$957.64M
52W High
$15.89
52W Low
$7.81
ADV30
762,080
Next earnings
2026-11-03
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 153,208,000 105,666,000 18,712,000 33,441,000 673,346,000 29,457,000 395,934,000
Mar 2026 132,089,000 90,769,000 8,870,000 3,113,000 650,539,000 35,846,000 416,274,000
Dec 2025 157,900,000 108,782,000 21,721,000 14,755,000 683,559,000 51,238,000 455,112,000
Sep 2025 138,651,000 94,229,000 11,251,000 3,155,000 701,593,000 42,164,000 494,338,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$96,873,000
Investing CF
$-4,087,000
Financing CF
$-95,000,000
CapEx
$-2,587,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.77
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-298,375,000
Inventory
$79,807,000
Receivables
$138,406,000
ST Investments
EBIT TTM
$58,515,000
Pretax Income TTM
$38,638,000
Interest Exp TTM
$19,877,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$581,848,000
EBITDA
$80,145,000
Free Cash Flow
$67,764,128
Enterprise Value
$1,240,099,072
Total Cash
$30,394,000
Total Debt
$263,748,992
Shares Out
68,305,143
Trailing EPS
$0.76
Book Value
$3.35
ROE
25.7%
ROA
5.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 568,087,000 56,291,000 22,732,000 683,559,000 455,112,000 74,673,000
Dec 2024 573,280,000 22,825,000 -36,125,000 727,956,000 542,352,000 38,795,000
Dec 2023 512,345,000 2,026,000 -156,230,000 810,910,000 589,792,000 15,344,000
Dec 2022 512,117,000 -34,656,000 -158,704,000 1,372,649,000 960,427,000 -13,537,000

TTM Snapshot

Revenues TTM
$138,964,000
NetIncome TTM
$-5,165,000
OpCashFlow TTM
$0
Assets (Latest)
$727,956,000
Forward EPS
$0.92

Max Pain — expiry 2027-01-15

max pain strike: $7.50 · spot: $14.03 · call oi: 1,555 · put oi: 31
Expected Move to 2027-01-15: ±$4.05 (28.87%) — implied range $9.98$18.08 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CBLL Ceribell, Inc. $918.77M $23.94
BBNX Beta Bionics, Inc. $887.65M $19.73
SGP SpyGlass Pharma, Inc. $878.34M $26.26
INMD InMode Ltd. $868.92M $15.10
SIBN SI-BONE, Inc. $863.48M $19.47

News headlines (Yahoo Finance, 1h cache)

Bioventus (BVS) Q2 2026 Earnings Call Transcript
2026-08-13 13:17 · Yahoo
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
2026-08-10 20:10 · Yahoo
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
2026-08-10 07:10 · Yahoo
Is Bioventus (BVS) Stock Undervalued Right Now?
2026-08-07 13:40 · Yahoo
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
2026-07-27 13:40 · Yahoo
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
2026-07-24 13:55 · Yahoo
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
2026-07-10 22:14 · Yahoo
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
2026-07-08 16:00 · Yahoo
Bioventus Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-08-24 13:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.